Skip to navigation Skip to content

Clinical Trial: Ocrelizumab in Progressive MS (CONSONANCE)


Treatment mode of action: To delay MS progression
Number of Subjects: 5
Medication: ocrelizumab
Location: Illinois|Indiana|Iowa|Michigan|Missouri|Wisconsin
Institutions: University of Chicago
5841 S Maryland Ave
Chicago, IL Contact Information
Please see below for contact information


Genentech, Inc


The purpose of the study is to see if Ocrelizumab will halt the worsening of the signs and symptoms of Progressive forms of MS. Smartphone-based “passive monitoring” of participants will also take place during the study. It will collect data on gait and mobility throughout the daily life of participants in a continuous and unobtrusive manner. For this, participants will be required to carry their smartphone preferably in a median position in a belt bag, or alternatively in their pocket as they go about their daily routine. They must carry the device for approximately four or more hours/day until it runs out of charge. 

The smartphone-based application also will prompt and self-guide the user to perform various assessments, referred to as “active tests.” These will be performed by the participants include the following and take approximately 5 minutes in total and should be performed at a consistent time each day: 
 - Cognitive, gait and posture tests.
 - Hand motor function tests: Test 1: Draw a Shape, test 2: Pinching

Participants may qualify for substudies involving MRI or optical coherence tomography (OCT).

Contact Name: Sravya Aluri or Mildred Valentine or the Study PI: Dr. Reder    
Phone: 7737044654 (Sravya) or 7737029812 (Mildred) 
Email: (Sravya) or (Mildred) or (Dr. Reder)


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.